FDA Approves First CRISPR/Cas9 Therapy

Congratulations to 1996 BYI Jennifer Doudna, PhD on the FDA approval of the first CRISPR/Cas9 gene editing therapy for patients struggling with sickle cell disease! “Gene therapy holds the promise of delivering more targeted and effective treatments, especially for individuals with rare diseases where the current treatment options are limited,” said Nicole Verdun, M.D., director of the Office of Therapeutic Products within the FDA’s Center for Biologics Evaluation and Research.